SAN FRANCISCO & SALT LAKE CITY--(BUSINESS WIRE)--IDbyDNA, a metagenomics technology company setting a new standard for the identification and understanding of microorganisms and their role in human health, today announced the appointment of two new members to its Scientific Advisory Board (SAB).
“On behalf of all of us at IDbyDNA, I would like to welcome Dr. Eddy Rubin and Dr. Alan T. Wright to our Scientific Advisory Board,” said Guochun Liao, Ph.D., IDbyDNA’s Founder, President & Chief Executive Officer. “Their experience and expertise in genomics and diagnostics will bring additional depth to an already distinguished SAB. We appreciate their commitment to helping guide the development of our metagenomics technology and the Explify® platform to improve the diagnosis and ultimately the treatment of infectious diseases.”
The IDbyDNA SAB is comprised of world leaders in infectious diseases (ID), human and microbial genomics, medical microbiology and bioinformatics. The advisory board serves as a strategic resource for IDbyDNA as it advances the application of its Explify platform, a comprehensive, diagnostic-grade technology used to profile tens of thousands of microorganisms, including pathogens and the human microbiome, among its partners around the world.
IDbyDNA Scientific Advisory Board Members
Carrie L. Byington, M.D.
Carrie
L. Byington, M.D., is a national leader in pediatrics and infectious
disease and serves as Dean of the Texas A&M College of Medicine, Senior
Vice President of the Texas A&M University Health Science Center and
Vice Chancellor for Health Services at The Texas A&M University System.
Dr. Byington was previously the H.A. and Edna Benning Presidential
Professor of Pediatrics, Vice Dean for Academic Affairs and Faculty
Development in the School of Medicine, and Associate Vice President for
Faculty and Academic Affairs at the University of Utah Health Sciences
Center during a 21-year career at the University of Utah. Dr. Byington
is board certified in both General Pediatrics and Pediatric Infectious
Diseases. She received a Bachelor of Science in biology from Texas A&M
University and Doctor of Medicine from Baylor College of Medicine.
Gene Myers, Ph.D.
Gene Myers is
a computer scientist and biotechnologist known for the BLAST search
engine and the sequencing of the human genome. He currently serves as
the Managing Director of the Max-Planck Institute of Molecular Cell
Biology and Genetics (MPI-CBG). Previously, Dr. Myers had been a group
leader at the HHMI Janelia Farm Research Campus (JFRC) since its
inception in 2005. Before that he was on the faculty of Computer Science
at UC Berkeley from 2003 to 2005. He was formerly Vice President of
Informatics Research at Celera Genomics where he and his team determined
the sequences of the Drosophila, Human, and Mouse genomes using the
whole genome shotgun technique that he advocated in 1996. Prior to that
Dr. Myers was on the faculty of the University of Arizona for 17 years.
He is a member of the National Academy of Engineering, USA, the National
Academy of Germany, and was awarded the ACM Kannellakis Prize in 2002.
Dr. Myers received a Bachelor of Science in Mathematics from California
Institute of Technology and a Ph.D. in Computer Science from the
University of Colorado.
George Weinstock, Ph.D.
Dr.
George Weinstock is a Professor and Director of Microbial Genomics at
the Jackson Laboratory for Genomic Medicine where he established a group
devoted to genomic studies of infectious diseases and the human
microbiome. Prior to joining the Jackson Laboratory, Dr. Weinstock
served as Associate Director of The Genome Institute at Washington
University in St. Louis. In addition, he was Co-Director of the Human
Genome Sequencing Center (HGSC), and Professor of Molecular and Human
Genetics at Baylor College of Medicine. Dr. Weinstock received his B.S.
from the University of Michigan and a Ph.D. from the Massachusetts
Institute of Technology.
John W.A. Rossen, Ph.D., M.Sc.
Dr.
John W.A. Rossen is a Professor of Medical Microbiology at the
University of Groningen in the Netherlands where he currently leads the
Personalized Microbiology Research Group which focuses on implementing
metagenomics and metatranscriptomics in the clinical setting. He also
serves as Head of the Molecular Unit. Under his leadership the group has
successfully utilized next generation sequencing to detect and
characterize pathogens, reveal new antibiotic resistance mechanisms,
prevent infection and improve risk assessment, and to develop novel
targeted diagnostic tests. In his 30 years in molecular virology and
molecular microbiology, Dr. Rossen has published more than 155 peer
reviewed studies. He currently serves as the secretary of the European
Society of Clinical Microbiology and Infectious Diseases (ESCMID) study
group for genomic and molecular diagnostics and Treasurer of the Dutch
Society of Medical Microbiology.
Eddy Rubin M.D., Ph.D.
Dr. Eddy
Rubin is a geneticist and medical researcher whose research includes a
series of pioneering studies in the field of human and microbial
genomics. While serving as Director of the Department of Energy Joint
Genome Institute (JGI) at the Lawrence Berkeley National Laboratory, his
team made significant contributions to the Human Genome Project and the
sequencing and analysis of thousands of plant, fungal and microbial
genomes. In 2016 he joined Metabiota, a company focused on applying
comprehensive risk analytics, as Chief Scientific Officer to help
organizations understand and mitigate infectious disease risk. Dr. Rubin
received a Bachelor of Arts in Physics from the University of California
San Diego and his M.D. and a Ph.D. in Biophysics from the University of
Rochester. He completed his medical residency in pediatrics, and his
clinical training in Human Genetics at the University of California San
Francisco.
Alan T. Wright M.D., M.P.H.
Alan
Wright is the Chief Medical Officer at Roche Diagnostics Corporation.
Prior to joining Roche, Dr. Wright served as Senior Vice President of
Health Improvement at Caris Life Sciences where he directed managed care
and reimbursement strategy and created an enterprise-wide regulatory and
advocacy strategy. Before joining Caris, Dr. Wright held executive
management positions in the health insurance, pharmaceutical and
pharmacy benefit management industries. Dr. Wright received a Bachelor
of Science in pre-medicine from Penn State University, an MD from the
University of Pennsylvania School of Medicine and a Master of Public
Health from the Johns Hopkins School of Medicine.
About IDbyDNA
IDbyDNA has developed transformative
metagenomics technology to simultaneously profile tens of thousands of
microorganisms and pathogens in any sample. Our turn-key Explify
Platform easily integrates into medical laboratories to deliver
actionable information to healthcare providers. Working with our global
partners, we are setting the standard for the identification and
understanding of microorganisms and their role in human health. http://www.idbydna.com/
